References:
- National Asbestos Profile - India - (http://www.amrc.org.hk/content/national-asbestos-profile-india)
- Asbestos Related Diseases in India - (http://worldasbestosreport.org/articles/iatb/page55.pdf)
- Michele Carbone and Haining Yang. Targeting Mechanisms of Asbestos and Erionite Carcinogenesis in Mesothelioma. Clin Cancer Res. 2012; 18(3): 598–604
- Angela Bononi, Andrea Napolitano, Harvey I Pass, Haining Yang, and Michele Carbone. Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies. Expert Rev Respir Med. 2015; 9(5): 633–654.
- Richard Morgan, Guy Simpson, Sophie Gray, Cheryl Gillett, Zsuzsanna Tabi, James Spicer, Kevin J. Harrington, Hardev S. Pandha. HOX transcription factors are potential targets and markers in malignant mesothelioma. BMC Cancer, 2016; 16 (1).
- Ando H, et al, “Advanced therapeutic approach for the treatment of malignant pleural mesothelioma via the intrapleural administration of liposomal pemetrexed”, 2015, Journal of Controlled Release.
- “FDA approves Keytruda for advanced non-small cell lung cancer”, October 2, 2015, FDA website.
- Sharkey, AJ, et al “The effects of an intentional transition from extrapleural pneumonectomy to extended pleurectomy/decortication”, 2015, European Journal of Cardiothoracic Surgery.
- Santarelli, L, et al, “Combined circulating epigenetic markers to improve mesothelin performance in the diagnosis of malignant mesothelioma”, 2015, Lung Cancer.
- Saoirse O Dolly, Cristina Migali, Nina Tunariu, Chiara Della-Pepa, Shelize Khakoo, Steve Hazell, Johann S de Bono, Stanley B Kaye, and Susana Banerjee. Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy ESMO Open. 2017; 2(1)
Editor: Dr. Simi Paknikar
Technically Checked by: Lingaraj
